Important Safety Information
Prescribing Information
Patient Support
Visit Our Patient Site
View Important Safety Information

IMPORTANT SAFETY INFORMATION:

Collapse Important Safety Information
Expand Important Safety Information

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

  • Do not prescribe Sucraid® to patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
  • Sucraid® may cause a serious allergic reaction. Patients should stop taking Sucraid® and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid® to observe any signs of acute hypersensitivity reaction.
  • Although Sucraid® provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.
  • Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
  • Before prescribing Sucraid® to diabetic patients, the physician should consider that Sucraid® will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
  • The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
  • DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
  • Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light; single-use containers can be removed from refrigeration and stored at 59°F-77°F (15°C-25°C) for up to 3 days (72 hours). Refer to Instructions for Use for full information on how to take Sucraid®.

Indication

Sucraid® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.

Prescribing Information DownloadPatient Websites HCP Websites menu

Visit Patient Site

View Important Safety Information

IMPORTANT SAFETY INFORMATION:

Dosing

Dosage and Administration

Please follow the dosing instructions carefully.

In This Section

The recommended Sucraid® dose is based on one’s body weight

The proper Sucraid® dose depends on the patient’s body weight.

  • For individuals who weigh up to 33 lb (15 kg), the Sucraid® dose is 1 mL
  • For individuals who weigh more than 33 lb (15 kg), the Sucraid® dose is 2 mL

Sucraid® is available two ways, in bottles that contain 118 mL (4 fluid oz) and single-use containers that each hold a 2-mL dose.

Recommended dosing for Sucraid® bottles:

  • 1 mL (8,500 IU, one full measuring scoop) per meal or snack for patients up to 33 lb (15 kg) in body weight
  • 2 mL (17,000 IU, 2 full measuring scoops) per meal or snack for patients over 33 lb (15 kg) in body weight

Each Sucraid® dose should be diluted in 4 ounces of water, milk or infant formula. Sucraid® can be measured with the 1 mL-measuring scoop (provided).

Recommended dosing for Sucraid® single-use containers:

The contents of the Sucraid® 2-ml single-use container should be diluted in 4 ounces of water, milk, or infant formula. Patients should consume:

  • all of the mixed solution dose per meal or snack for patients over 33 lb (15 kg) in body weight
  • half of the mixed solution dose per meal or snack for patients 33 lb (15 kg) and less
Sucraid® Single Use Container

Administration, Storage, and Shelf Life

The following should be noted with regard to the administration:

  • Half of each dose should be taken before the meal and the other half during the meal
  • The beverage or infant formula used to dilute Sucraid® should not be heated, nor should Sucraid® be added to hot beverages, as heat can decrease the potency of the enzyme
  • Sucraid® should not be reconstituted or consumed with fruit juices, as the acidity may impair enzyme activity
  • For patients 33 lb (15 kg) and less using the Sucraid® 2-ml single-use container, the second half of the mixed solution should be refrigerated and discarded if not used within 24 hours

Storage and shelf life of Sucraid®:

  • Sucraid® should be refrigerated at 36°F to 46°F (2°C to 8°C) and protected from heat and light
  • Bottles of Sucraid® should be discarded four weeks after first opening due to the potential for bacterial growth
  • Single-use containers of Sucraid® can be removed from refrigeration and stored at 15°C to 25°C (59°F to 77°F) for up to 3 days (72 hours)

Healthcare professionals may recommend that patients avoid dietary sources of starch for the first two weeks of Sucraid® treatment, then gradually add starch back into the diet while monitoring symptoms, as Sucraid® does not address isomaltase deficiency.

Learn How to Order Sucraid® from Our Specialty Pharmacy

References
  1. Sucraid® [package insert]. Vero Beach, FL: QOL Medical, LLC; 2024.

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

  • Do not prescribe Sucraid® to patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
  • Sucraid® may cause a serious allergic reaction. Patients should stop taking Sucraid® and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid® to observe any signs of acute hypersensitivity reaction.
  • Although Sucraid® provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.
  • Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
  • Before prescribing Sucraid® to diabetic patients, the physician should consider that Sucraid® will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
  • The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
  • DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
  • Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light; single-use containers can be removed from refrigeration and stored at 59°F-77°F (15°C-25°C) for up to 3 days (72 hours). Refer to Instructions for Use for full information on how to take Sucraid®.

Indication

Sucraid® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.